Clinical trial
Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid…
NCT01297699 · Hospital Clinico Universitario de Santiago, Other · Completed
Key facts
| NCT number | NCT01297699 |
|---|---|
| Title | Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) |
| Official title | Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to… |
| Acronym | GRC |
| Lead sponsor | Hospital Clinico Universitario de Santiago, Other |
| Collaborators | Fundación Ramón Domínguez |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy, Thyroid Eye Disease |
| Intervention type | Drug |
| Interventions | Tocilizumab (RoActemra®), Sterile 0.9% Sodium Chloride |
| Enrollment | 32 |
| Start date | Mar 1, 2012 |
| Primary completion | Oct 1, 2015 |
| Completion | Dec 1, 2015 |
| First posted | Feb 17, 2011 |
| Last update posted | Jan 20, 2016 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: